Showing results (111-120 of 324) with videos related to
Sort By:
Pageof 33
Lung Cancer (Amsterdam, Netherlands)|November 21, 2007
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatmentZhong-Zhe Lin, Chiun Hsu, Yeun-Chung Chang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL studyAlex Chang, Purvish Parikh, Sumitra Thongprasert, et al.The Oncologist|June 8, 2012
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapyZhong-Zhe Lin, Chiun Hsu, Fu-Chang Hu, et al.Clinical Lung Cancer|May 30, 2016
Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung CancerShun Lu, Ying Cheng, Cai-Cun Zhou, et al.Targeted Oncology|January 18, 2023
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic StrategiesSanjay Popat, Myung-Ju Ahn, Simon Ekman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung CancerGeoffrey R Oxnard, Kenneth S Thress, Ryan S Alden, et al.Hepato-Gastroenterology|May 18, 2004
Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinomaYen-Shen Lu, Chiun Hsu, Chi-Cheng Li, et al.Lung Cancer (Amsterdam, Netherlands)|March 1, 2021
Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysisPeey-Sei Kok, Kirsty Lee, Sally Lord, et al.Future Oncology (London, England)|August 11, 2022
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancerMasahiro Tsuboi, Jonathan W Goldman, Yi-Long Wu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 22, 2017
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of OsimertinibSuzanne Jenkins, James Chih-Hsin Yang, Pasi A Jänne, et al.Pageof 33